Hospital-Level Variability in Reporting of Ischemic Stroke Subtypes and Supporting Diagnostic Evaluation in GWTG-Stroke Registry.

"Disclosures Dr. Gurol reports funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, and research funding to Massachusetts General Hospital from AVID (a wholly owned subsidiary of Eli Lilly), Boston Scientific Corporation, and Pfizer. Dr Fonarow reports funding from PCORI, participating in the GWTG‐Stroke Steering Committee, and being an employee of UC Regents, which have a patent on an endovascular device. Dr. Messé reports participation in the GWTG‐Stroke Steering Committee and is cofounder of Neuralert Technologies, which is developing a device to detect stroke. Dr Prabhakaran reports funding from the Agency for Healthcare Research and Quality and the National Institute of Neurological Disorders and Stroke as well as royalties from UpToDate on cryptogenic stroke. Dr Mullen reports royalties from UpToDate on topics related to the evaluation and management of ischemic stroke and participation in the GWTG‐Stroke Systems of Care Advisory Group. Dr Schwamm reports funding from Patient‐Centered Outcomes Research Institute and the National Institute of Neurological Disorders and Stroke, participating in the GWTG‐Stroke Systems of Care Advisory Group, and serving as a consultant to Medtronic and national co–principal investigator of the Stroke‐AF (Stroke of Known Cause and Underlying Atrial Fibrillation) trial of long‐term insertable cardiac rhythm monitoring sponsored by Medtronic. The remaining authors have no disclosures to report."

"Sources of Funding The GWTG‐Stroke (Get With The Guidelines–Stroke) program is provided by the American Heart Association/American Stroke Association. GWTG‐Stroke is sponsored, in part, by Novartis, Novo Nordisk, AstraZeneca, Bayer, Tylenol and Alexion, and AstraZeneca Rare Disease."